Developer docs
API playgroundTry for free, no card

Search company profiles

Shennon Biotechnologies

Full company profile

uuid0000fkg

Namestring
Shennon Biotechnologies
Legal namestring
Shennon Biotechnologies Inc.
Websiteurl
shennonbio.com
Company typeenum
Private
Founded yearint
2021
Descriptiontext

Shennon Biotechnologies is a privately held, pre-revenue biotech company founded in 2021 and based in San Francisco that develops a proprietary single-cell functional immune profiling platform for immunotherapy drug discovery. The company's core technology stack is built around three named components: TCELERATORTM, an ultrafast functional screening platform that dynamically profiles tens of millions of single cell-cell interactions to identify rare disease-relevant populations; PINTATM, an AI engine that integrates multidimensional tumor and normal sample data to discover novel therapeutic targets for previously 'undruggable' diseases; and SERISTM, an AI model that analyzes normal human tissue molecular data to predict potential cross-reactivity and clinical toxicity of drug candidates. The company states that SERISTM has predicted 100% of previously reported toxicity events and that the combined platform can halve drug development timelines.

The company targets pharmaceutical and biotechnology companies developing immunotherapies for cancer (with emphasis on solid tumors) and autoimmune diseases, addressing pain points such as difficulty identifying rare disease-relevant cell populations, slow and costly target discovery, high clinical failure rates from unpredicted toxicities, and limited treatment options for 'undruggable' indications. Its go-to-market is a B2B enterprise motion executed through direct engagement with pharma partners, supported by a scientific advisory board that includes former senior R&D leaders from Eli Lilly, J&J, Bristol Myers Squibb, and Pfizer, and academic experts from Harvard, MSKCC, UCSF, Weill Cornell, and Fred Hutch.

Shennon's business model is structured around technology platform licensing and co-development partnerships with pharmaceutical companies, with expected revenue streams including upfront payments, research funding, milestone payments, and royalties; the company has not yet announced any signed commercial agreements and remains pre-revenue as of November 2025. The company has raised $13 million in a March 2023 seed round led by DCVC with participation from Foundation Capital, AV8 Ventures, angel investors, and several additional VC firms listed on the company website, and is actively hiring across immunology (T cell engager and TCR-T cell therapy programs) and machine learning research functions.

Short descriptiontext

Shennon Biotechnologies is a pre-revenue, San Francisco-based biotech founded in 2021 that combines an ultrafast single-cell functional screening platform (TCELERATOR) with proprietary AI models (PINTA, SERIS) to discover novel immunotherapy targets and predict clinical safety for pharmaceutical and biotech partners developing cancer and autoimmune disease treatments.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Francisco, United States
HQ citystring
San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
single-cell screening, immunotherapy discovery, drug development platform, functional cell profiling, AI toxicity prediction
Industry2 codes
PRIMARYHLAAAIAF
Single-Cell & Spatial Omics Discovery Platforms (target ID/validation, functional profiling)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Biotechnology Drug Discovery Platform
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Technology Platform Licensing and Partnerships
TypeLicensing Royalties
Description

Pre-revenue biotech company. Revenue model likely to include licensing of technology platform to pharmaceutical companies, co-development partnerships, and milestone-based payments from drug development collaborations. The company develops proprietary technology for immunotherapy target discovery that can be offered to pharma partners.

shennonbio.com
2Drug Discovery Co-development
TypeProfessional Services
Description

Strategic co-development arrangements with pharmaceutical companies for specific therapeutic targets, potentially generating upfront payments, research funding, and downstream milestone and royalty payments.

shennonbio.com
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 3 records shown
1TCELERATORTM
Description

Proprietary platform that enables ultrafast functional and dynamic profiling of millions of single cell interactions to find rare populations and screen for immune modulating agents by specific function.

shennonbio.com
+2 more records
Core offering1 text field

Shennon Biotechnologies develops a proprietary single-cell functional immune profiling platform that combines ultrafast high-throughput screening of tens of millions of cell-cell interactions with proprietary AI models to discover novel immunotherapy targets and predict clinical safety for cancer and autoimmune disease drug development. Its three named offerings — TCELERATORTM, PINTATM and SERISTM — together form a technology stack licensed or co-developed with pharmaceutical and biotechnology partners rather than sold as standalone off-the-shelf products.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Cuts drug development time in half while ensuring safety by predicting clinical failures
+1 more record
Product overview1 text field

Shennon Biotechnologies operates as a unified platform company combining three core proprietary technologies. The TCELERATORTM platform provides ultrafast functional single-cell screening at tens of millions of events per run. PINTATM is an AI engine for novel target discovery from multidimensional tumor and normal sample datasets. SERISTM is an AI safety model for predicting clinical toxicity. Together, these technologies enable faster and safer immunotherapy development for cancer and autoimmune diseases.

Product and service3 records
1TCELERATORTM
CategorySingle-cell functional screening platform
Description

TCELERATORTM is a proprietary ultrafast functional screening platform that dynamically probes tens of millions of single cell-cell interactions, enabling high-throughput identification and characterization of rare cell populations and screening of therapeutic agents by specific function. It is offered to pharmaceutical and biotech companies developing immunotherapies for cancer and autoimmune diseases.

2PINTATM
CategoryAI drug discovery engine
Description

PINTATM is a proprietary AI engine that integrates multiple dimensions of data from a large set of tumor and normal samples to discover therapeutically relevant, novel targets for previously 'undruggable' diseases, providing a therapeutic path for patients with limited or no treatment options. It is offered to pharmaceutical and biotech partners developing immunotherapies.

3SERISTM
CategoryAI clinical safety prediction
Description

SERISTM is an AI-driven deep molecular scanning model that analyzes molecular details of normal human tissues to look for potential cross-reactivity with drug candidates. It has reportedly predicted 100% of previously reported toxicity events, providing a safeguard for drug design. It is offered to pharmaceutical and biotech partners as a clinical safety prediction tool.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers8 records
TypeDirect peer
Description

Public leader in single-cell genomics and immune profiling platforms (Chromium, Visium). Competes with Shennon's TCELERATOR™ on the single-cell analysis layer that pharma discovery teams use, though 10x focuses on genomic profiling rather than ultrafast functional cell-cell interaction screening.

TypeDirect peer
Description

AI-enabled antibody discovery platform that partners with pharma to identify and develop therapeutic candidates from single B cells. Closely comparable to Shennon in applying single-cell + AI to immunotherapy target discovery and signing pharma licensing/co-development deals.

TypeDirect peer
Description

AI/ML-driven biologics platform focused on computationally designing novel protein therapeutics. Directly comparable to Shennon's PINTA™/SERIS™ AI engine approach and its pharma partnership business model around differentiated biologic targets.

TypeDirect peer
Description

Machine-learning-driven drug discovery company partnering with pharma (e.g., Bristol Myers Squibb, Eli Lilly) for target identification and development. Comparable to Shennon in combining AI/ML with biological data to enable pharma partnerships and platform-licensing economics.

TypeDirect peer
Description

Single-cell functional screening platform using optofluidic technology to profile immune cells and antibodies. Directly overlaps with TCELERATOR™'s functional profiling of immune cell-cell interactions for immunotherapy discovery.

TypeDirect peer
Description

Single-cell functional immune profiling platform used by pharma for cell therapy and immunotherapy development. Comparable to Shennon in serving pharma with single-cell functional data for immunotherapy target identification.

TypeEmerging player
Description

Clinical-stage immunotherapy company using AI-driven antibody discovery (POWER platform) to develop novel therapeutics. Comparable in AI-enabled immunotherapy discovery focus and pharma partnership orientation, though more advanced in clinical pipeline.

TypeEmerging player
Description

AI/ML-driven protein engineering platform for therapeutic antibody and enzyme design. Notable comparable because Tek Hyung Lee, Shennon's Senior Scientist, previously worked at BioMap on TCE engineering — reflecting similar AI+bio approach to immuno-therapeutic design.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles21 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Shennon Biotechnologies

Biotechnology Drug Discovery Platformshennonbio.com

Shennon Biotechnologies is a pre-revenue, San Francisco-based biotech founded in 2021 that combines an ultrafast single-cell functional screening platform (TCELERATOR) with proprietary AI models (PINTA, SERIS) to discover novel immunotherapy targets and predict clinical safety for pharmaceutical and biotech partners developing cancer and autoimmune disease treatments.

What Shennon Biotechnologies does

Shennon Biotechnologies is a privately held, pre-revenue biotech company founded in 2021 and based in San Francisco that develops a proprietary single-cell functional immune profiling platform for immunotherapy drug discovery. The company's core technology stack is built around three named components: TCELERATORTM, an ultrafast functional screening platform that dynamically profiles tens of millions of single cell-cell interactions to identify rare disease-relevant populations; PINTATM, an AI engine that integrates multidimensional tumor and normal sample data to discover novel therapeutic targets for previously 'undruggable' diseases; and SERISTM, an AI model that analyzes normal human tissue molecular data to predict potential cross-reactivity and clinical toxicity of drug candidates. The company states that SERISTM has predicted 100% of previously reported toxicity events and that the combined platform can halve drug development timelines.

The company targets pharmaceutical and biotechnology companies developing immunotherapies for cancer (with emphasis on solid tumors) and autoimmune diseases, addressing pain points such as difficulty identifying rare disease-relevant cell populations, slow and costly target discovery, high clinical failure rates from unpredicted toxicities, and limited treatment options for 'undruggable' indications. Its go-to-market is a B2B enterprise motion executed through direct engagement with pharma partners, supported by a scientific advisory board that includes former senior R&D leaders from Eli Lilly, J&J, Bristol Myers Squibb, and Pfizer, and academic experts from Harvard, MSKCC, UCSF, Weill Cornell, and Fred Hutch.

Shennon's business model is structured around technology platform licensing and co-development partnerships with pharmaceutical companies, with expected revenue streams including upfront payments, research funding, milestone payments, and royalties; the company has not yet announced any signed commercial agreements and remains pre-revenue as of November 2025. The company has raised $13 million in a March 2023 seed round led by DCVC with participation from Foundation Capital, AV8 Ventures, angel investors, and several additional VC firms listed on the company website, and is actively hiring across immunology (T cell engager and TCR-T cell therapy programs) and machine learning research functions.

Shennon Biotechnologies firmographics

Firmographics
Name
Shennon Biotechnologies
Legal name
Shennon Biotechnologies Inc.
Website
https://shennonbio.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
11–50 employees
Short description
Shennon Biotechnologies is a pre-revenue, San Francisco-based biotech founded in 2021 that combines an ultrafast single-cell functional screening platform (TCELERATOR) with proprietary AI models (PINTA, SERIS) to discover novel immunotherapy targets and predict clinical safety for pharmaceutical and biotech partners developing cancer and autoimmune disease treatments.
Ownership category
akta.pro rank

Shennon Biotechnologies industry classification

Industry
Product category
Biotechnology Drug Discovery Platform
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAAIAF
Single-Cell & Spatial Omics Discovery Platforms (target ID/validation, functional profiling)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Single-cell screening
  • Immunotherapy discovery
  • Drug development platform
  • Functional cell profiling
  • AI toxicity prediction

Where Shennon Biotechnologies is headquartered

Location

Headquarters

HQ city
San Francisco
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Shennon Biotechnologies business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Technology Platform Licensing and Partnerships: Pre-revenue biotech company. Revenue model likely to include licensing of technology platform to pharmaceutical companies, co-development partnerships, and milestone-based payments from drug development collaborations. The company develops proprietary technology for immunotherapy target discovery that can be offered to pharma partners.
  2. Drug Discovery Co-development: Strategic co-development arrangements with pharmaceutical companies for specific therapeutic targets, potentially generating upfront payments, research funding, and downstream milestone and royalty payments.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Shennon Biotechnologies product offering

Product offering

Core offering

Shennon Biotechnologies develops a proprietary single-cell functional immune profiling platform that combines ultrafast high-throughput screening of tens of millions of cell-cell interactions with proprietary AI models to discover novel immunotherapy targets and predict clinical safety for cancer and autoimmune disease drug development. Its three named offerings — TCELERATORTM, PINTATM and SERISTM — together form a technology stack licensed or co-developed with pharmaceutical and biotechnology partners rather than sold as standalone off-the-shelf products.

Product overview

Shennon Biotechnologies operates as a unified platform company combining three core proprietary technologies. The TCELERATORTM platform provides ultrafast functional single-cell screening at tens of millions of events per run. PINTATM is an AI engine for novel target discovery from multidimensional tumor and normal sample datasets. SERISTM is an AI safety model for predicting clinical toxicity. Together, these technologies enable faster and safer immunotherapy development for cancer and autoimmune diseases.

Differentiator

Problem solved

Functional benefit

Brands

  • TCELERATORTM: Proprietary platform that enables ultrafast functional and dynamic profiling of millions of single cell interactions to find rare populations and screen for immune modulating agents by specific function.
  • PINTATM
  • SERISTM

Products and services

  • TCELERATORTM TCELERATORTM is a proprietary ultrafast functional screening platform that dynamically probes tens of millions of single cell-cell interactions, enabling high-throughput identification and characterization of rare cell populations and screening of therapeutic agents by specific function. It is offered to pharmaceutical and biotech companies developing immunotherapies for cancer and autoimmune diseases.
  • PINTATM PINTATM is a proprietary AI engine that integrates multiple dimensions of data from a large set of tumor and normal samples to discover therapeutically relevant, novel targets for previously 'undruggable' diseases, providing a therapeutic path for patients with limited or no treatment options. It is offered to pharmaceutical and biotech partners developing immunotherapies.
  • SERISTM SERISTM is an AI-driven deep molecular scanning model that analyzes molecular details of normal human tissues to look for potential cross-reactivity with drug candidates. It has reportedly predicted 100% of previously reported toxicity events, providing a safeguard for drug design. It is offered to pharmaceutical and biotech partners as a clinical safety prediction tool.

Quantifiable outcome

  • Cuts drug development time in half while ensuring safety by predicting clinical failures
  • +1 more outcomes

Companies that use Shennon Biotechnologies

Customer profile

Segments1 record

Ideal customer profiles1 record

Shennon Biotechnologies technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature4 records

Shennon Biotechnologies partnerships and signals

Strategic signal

Scale indicators3 records

Recent moves5 records

Expansion highlights4 records

Shennon Biotechnologies competitors and assessment

Company assessment

Direct peers

  • 10x Genomics: Public leader in single-cell genomics and immune profiling platforms (Chromium, Visium). Competes with Shennon's TCELERATOR™ on the single-cell analysis layer that pharma discovery teams use, though 10x focuses on genomic profiling rather than ultrafast functional cell-cell interaction screening.
  • AbCellera Biologics: AI-enabled antibody discovery platform that partners with pharma to identify and develop therapeutic candidates from single B cells. Closely comparable to Shennon in applying single-cell + AI to immunotherapy target discovery and signing pharma licensing/co-development deals.
  • Generate Biomedicines: AI/ML-driven biologics platform focused on computationally designing novel protein therapeutics. Directly comparable to Shennon's PINTA™/SERIS™ AI engine approach and its pharma partnership business model around differentiated biologic targets.
  • Insitro: Machine-learning-driven drug discovery company partnering with pharma (e.g., Bristol Myers Squibb, Eli Lilly) for target identification and development. Comparable to Shennon in combining AI/ML with biological data to enable pharma partnerships and platform-licensing economics.
  • Bruker Cellular Analysis (formerly Berkeley Lights): Single-cell functional screening platform using optofluidic technology to profile immune cells and antibodies. Directly overlaps with TCELERATOR™'s functional profiling of immune cell-cell interactions for immunotherapy discovery.
  • Standard BioTools (formerly IsoPlexis): Single-cell functional immune profiling platform used by pharma for cell therapy and immunotherapy development. Comparable to Shennon in serving pharma with single-cell functional data for immunotherapy target identification.

Emerging players

  • Adagene: Clinical-stage immunotherapy company using AI-driven antibody discovery (POWER platform) to develop novel therapeutics. Comparable in AI-enabled immunotherapy discovery focus and pharma partnership orientation, though more advanced in clinical pipeline.
  • BioMap: AI/ML-driven protein engineering platform for therapeutic antibody and enzyme design. Notable comparable because Tek Hyung Lee, Shennon's Senior Scientist, previously worked at BioMap on TCE engineering — reflecting similar AI+bio approach to immuno-therapeutic design.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

Shennon Biotechnologies social profiles

Digital presence

Shennon Biotechnologies financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Shennon Biotechnologies leadership team

Management profile

Number of profiles

Profiles21 records

Shennon Biotechnologies funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Shennon Biotechnologies M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Shennon Biotechnologies

What does Shennon Biotechnologies do?

Shennon Biotechnologies develops a proprietary single-cell functional immune profiling platform that combines ultrafast high-throughput screening of tens of millions of cell-cell interactions with proprietary AI models to discover novel immunotherapy targets and predict clinical safety for cancer and autoimmune disease drug development. Its three named offerings — TCELERATORTM, PINTATM and SERISTM — together form a technology stack licensed or co-developed with pharmaceutical and biotechnology partners rather than sold as standalone off-the-shelf products.

Is Shennon Biotechnologies a public or private company?

Shennon Biotechnologies is a private company. It is classified as venture growth investor backed and is currently operating.

When was Shennon Biotechnologies founded?

Shennon Biotechnologies was founded in 2021. It employs 11 to 50 people.

Where is Shennon Biotechnologies based?

Shennon Biotechnologies is headquartered in San Francisco, United States, in the North America region.

How does Shennon Biotechnologies make money?

Two revenue lines are on record. Technology Platform Licensing and Partnerships are the primary driver. The others are drug Discovery Co-development.

Who are Shennon Biotechnologies's main competitors?

Direct peers on record are 10x Genomics, AbCellera Biologics, Generate Biomedicines, Insitro, Bruker Cellular Analysis (formerly Berkeley Lights) and Standard BioTools (formerly IsoPlexis). Emerging players are Adagene and BioMap.

Does Shennon Biotechnologies have an API?

No public API is recorded for Shennon Biotechnologies.

What industry is Shennon Biotechnologies in?

Shennon Biotechnologies's product category is Biotechnology Drug Discovery Platform. Its primary akta.pro industry code is HLAAAIAF, Single-Cell & Spatial Omics Discovery Platforms (target ID/validation, functional profiling), with a secondary code of HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Venture Capital Access OnlineShennon Biotechnologies Raises $12M in Financing, Appoints Cyril Konto, M.D., as Chief Executive Officer and Unveils Precision Immunotherapy PipelineShennon Biotechnologies raised $12M in financing from multiple investors, bringing its total to $25M. The company appointed Cyril Konto as CEO, with founder Li Sun transitioning to President and CTO. The funds will advance three T-cell engager programs for small cell lung cancer, ovarian cancer, and hepatocellular carcinoma toward clinical development.The Pharma LetterShennon Biotechnologies raises $12 million, names CEO and unveils oncology pipelineShennon Biotechnologies raised $12 million in a financing round from Future Ventures, NextGen Venture Partners, Samos Investments, Atypical Ventures, and Saras Capital. The round brings total funding to $25 million since its 2021 founding. The company also named a CEO and unveiled an oncology pipeline.citybizShennon Biotechnologies Raises $12 Million, Names Cyril Konto CEOShennon Biotechnologies raised $12 million and appointed Cyril Konto as CEO, with founder Li Sun moving to president and CTO. The round brings total funding to $25 million, to advance three T-cell engager programs for small cell lung cancer, ovarian cancer, and hepatocellular carcinoma. The company plans to move a development candidate toward Phase 1 clinical trials over the next two years.Pulse 2.0Shennon Biotechnologies Raises $12 Million, Names Cyril Konto As CEO, And Unveils Precision Immunotherapy PipelineShennon Biotechnologies raised $12 million in financing and appointed Cyril Konto as CEO, bringing total capital to $25 million. The funds will advance three T-cell engager programs for small-cell lung cancer, ovarian cancer, and hepatocellular carcinoma. The company plans to advance a development candidate toward an IND filing within two years.BioSpaceShennon Biotechnologies Raises $12M in Financing, Appoints Cyril Konto, M.D., as Chief Executive Officer and Unveils Precision Immunotherapy PipelineShennon Biotechnologies raised $12M in financing and appointed Cyril Konto as CEO, with founder Li Sun moving to President and CTO. The company has raised $25M to date and is advancing three T-cell engager programs for small cell lung cancer, ovarian cancer, and hepatocellular carcinoma. It plans to advance a development candidate toward IND filing within two years.FinSMEsShennon Biotechnologies Raises $12M in FundingShennon Biotechnologies raised $12M in funding, bringing its total to $25M. The San Francisco-based biotech will use the funds to develop its integrated technology platform and advance its oncology pipeline, which includes three T-cell engager programs for small cell lung cancer, ovarian cancer, and hepatocellular carcinoma.Business Wire BlogShennon Biotechnologies Raises $12M in Financing, Appoints Cyril Konto, M.D., as Chief Executive Officer and Unveils Precision Immunotherapy PipelineShennon Biotechnologies raised $12M in financing and appointed Cyril Konto as CEO, with founder Li Sun moving to president and CTO. The company has raised $25M to date and is advancing three T-cell engager programs for small cell lung cancer, ovarian cancer, and hepatocellular carcinoma. It plans to advance a development candidate toward IND filing and Phase 1 within two years.SecSEC FORM DShennon Biotechnologies Inc. filed a Form D with the SEC for an exempt offering of securities under Rule 506(b), reporting total sales of $7,299,925 from nine investors. The filing indicates the company is a Delaware-based biotechnology firm incorporated in 2021, with its principal place of business in San Francisco. This regulatory submission formally notifies authorities of the private placement transaction.Venture Capital Access OnlineShennon Biotechnologies Raises $13M Seed Financing to Accelerate Immunotherapy Target Discovery with Proprietary Single-Cell Functional Screening PlatformShennon Biotechnologies announced the closing of a $13 million oversubscribed seed financing round led by DCVC, with participation from Foundation Capital and AV8. The company will utilize these funds to expand its proprietary single-cell functional screening platform and scale target discovery efforts for solid tumor immunotherapies. This development aims to overcome current bottlenecks in identifying rare immune cells for cancer treatments.FinSMEsShennon Biotechnologies Raises $13M in Seed FinancingShennon Biotechnologies raised $13 million in seed funding led by DCVC, with participation from Foundation Capital and AV8. The company intends to use the capital to expand its proprietary single-cell platform capabilities and scale discovery efforts for solid tumor immunotherapies.